摘要
目的对36例肛管癌患者进行生存分析,找出影响其预后的分子生物学及临床因子,探讨提高疗效的措施。方法应用免疫组化S-P法检测36例肛管癌标本中P33ING1的表达,用Log-rank检验及Cox回归分析其可能影响预后的11个因子。结果多因素分析显示,肿瘤淋巴结转移、手术方式、放疗、P33ING1表达等是影响其预后的分子生物学及临床因子。结论P33ING1低表达是预后差的生物学因子,增加P33ING1的表达是治疗肛管癌的新途径。早发现、早治疗是提高肛管癌5年生存率的关键。
Objective To analyze the clinicopathologic and biological factors affecting the prognosis of anal canal carcinoma. Methods The expression of P33^ING1 was examined in 36 cases of anal canal carcinoma. Eleven suspected prognosis factors were analyzed by log-rank test and Cox regression analysis. Result Multivariate analysis showed that lymphatic node metastasis, surgical technique, radiotherapy and P33^ING1 expression were the important prognosis factors. Conclusions Low expresssion of P33^ING1 seems to be a poor prognosis marker of anal canal carcinoma. Early discovery and radical surgery are pivotal for the improvement of 5-year survival rate in patients with anal canal carcinoma.
出处
《中国肿瘤临床与康复》
2007年第4期303-305,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
